Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00590109 · ClinicalTrials.gov registry record
Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer
A clinical trial, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- 383
- Enrollment target
NCT00590109: Completed study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00590109 is a clinical trial that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 383 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00590109 has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- 383 participants
- Enrollment target
Study Summary
The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.
Interventions
- OTHER Questionnaire
- OTHER Blood test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 383 participants |
| Start Date | 1997-03 |
| Est. Completion | 2021-12-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00590109
The ClinicalTrials.gov registry entry for NCT00590109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 383 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Questionnaire is the first listed.
NCT00590109 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00590109 about?
NCT00590109 is a clinical study titled "Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer". The purpose of this project is to further characterize inherited predisposition to breast cancer mediated by specific BRCA alleles (BRACA1 185delAG and 5382insC; BRCA2 6174delT) among Jewish women.
What is the current status of trial NCT00590109?
This trial is currently completed. The enrollment target is 383 participants. The study started on 1997-03. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT00590109?
The interventions under investigation include: Questionnaire (OTHER), Blood test (OTHER).
Who is sponsoring clinical trial NCT00590109?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.